
Katja Strohfeldt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2480057/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Bioorganometallic fulvene-derived titanocene anti-cancer drugs. Chemical Society Reviews, 2008, 37, 1174.	18.7	310
2	Novel benzyl substituted titanocene anti-cancer drugs. Journal of Organometallic Chemistry, 2005, 690, 4537-4544.	0.8	118
3	In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes. Anti-Cancer Drugs, 2005, 16, 1091-1098.	0.7	105
4	The Crystal Structures of the Chiral Alkyllithium Bases [n-BuLi·(â^')-Sparteine]2and [Et2O·(i-PrLi)2·(â^')-Sparteine]. Journal of the American Chemical Society, 2003, 125, 13672-13673.	6.6	79
5	[tBuLiâ‹(â^')-Sparteine]: Molecular Structure of the First Monomeric Butyllithium Compound. Angewandte Chemie - International Edition, 2003, 42, 4531-4533.	7.2	73
6	Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice. Anti-Cancer Drugs, 2006, 17, 333-336.	0.7	69
7	Heteroaryl substitutedansa-titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. Applied Organometallic Chemistry, 2005, 19, 293-300.	1.7	68
8	Crystal Structures of (+)-Sparteine Surrogate Adducts of Methyllithium and Phenyllithium. Organometallics, 2004, 23, 5389-5391.	1.1	63
9	Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice. Anti-Cancer Drugs, 2007, 18, 311-315.	0.7	50
10	Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour. European Journal of Pharmacology, 2006, 534, 264-270.	1.7	46
11	Antiproliferative activity of Titanocene Y against tumor colony-forming units. Anti-Cancer Drugs, 2007, 18, 317-321.	0.7	46
12	Activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride against tumor colony-forming units. Anti-Cancer Drugs, 2005, 16, 1071-1073.	0.7	45
13	Crystal Structures of [PhLi·(â^')-sparteine]2, [PhOLi·(â^')-sparteine]2, and the Mixed Aggregate [PhLi·PhOLi·2(â^')-sparteine]. Organometallics, 2006, 25, 41-44.	1.1	45
14	Synthesis and cytotoxicity studies of new dimethylamino-functionalised and heteroaryl-substituted titanocene anti-cancer drugs. Journal of Organometallic Chemistry, 2007, 692, 2153-2159.	0.8	45
15	Proliferative and anti-proliferative effects of titanium- and iron-based metallocene anti-cancer drugs. Journal of Organometallic Chemistry, 2009, 694, 874-879.	0.8	43
16	Ruthenium-conjugated chrysin analogues modulate platelet activity, thrombus formation and haemostasis with enhanced efficacy. Scientific Reports, 2017, 7, 5738.	1.6	41
17	A trimethoxyphenyl substituted ansa-titanocene: A possible anti-cancer drug. Polyhedron, 2005, 24, 1250-1255.	1.0	40
18	Heteroaryl substituted titanocenes as potential anti-cancer drugs. Journal of Inorganic Biochemistry, 2006, 100, 1479-1486.	1.5	40

Katja Strohfeldt

#	Article	IF	CITATIONS
19	Silylâ€Modified Analogues of 2â€Tritylpyrrolidine: Synthesis and Applications in Asymmetric Organocatalysis. Chemistry - A European Journal, 2010, 16, 12553-12558.	1.7	37
20	Diarylmethyl substituted titanocenes: Promising anti-cancer drugs. Polyhedron, 2006, 25, 2101-2108.	1.0	32
21	Diheteroarylmethyl substituted titanocenes: A novel class of possible anti-cancer drugs. Inorganica Chimica Acta, 2006, 359, 3969-3975.	1.2	30
22	Synthesis and cytotoxicity studies of new dimethylamino-functionalised and aryl-substituted titanocene anti-cancer agents. European Journal of Medicinal Chemistry, 2008, 43, 122-128.	2.6	30
23	The synthesis and cytotoxic evaluation of a series of benzodioxole substituted titanocenes. Applied Organometallic Chemistry, 2007, 21, 57-65.	1.7	27
24	A Model for Self-Directed Problem-Based Learning for Renal Therapeutics. American Journal of Pharmaceutical Education, 2010, 74, 173.	0.7	25
25	Analysis of Three Epoetin Alpha Products by LC and LC-MS Indicates Differences in Glycosylation Critical Quality Attributes, Including Sialic Acid Content. Analytical Chemistry, 2017, 89, 6455-6462.	3.2	25
26	Antitumor Activity of Titanocene Y in Xenografted PC3 Tumors in Mice. Letters in Drug Design and Discovery, 2008, 5, 141-144.	0.4	24
27	Glycol Methyl Ether and Glycol Amine Substituted Titanocenes as Antitumor Agents. European Journal of Inorganic Chemistry, 2006, 2006, 4621-4628.	1.0	23
28	Using Problem-Based Learning in a Chemistry Practical Class for Pharmacy Students and Engaging Them with Feedback. American Journal of Pharmaceutical Education, 2015, 79, 141.	0.7	21
29	Synthesis and cytotoxicity studies of new dimethylamino-functionalised and indolyl-substituted titanocene anti-cancer drugs. Transition Metal Chemistry, 2007, 32, 434-441.	0.7	18
30	Titanocene anticancer complexes and their binding mode of action to human serum albumin: A computational study. Metallomics, 2011, 3, 152.	1.0	18
31	Proliferative and antiproliferative effects in substituted titanocene anticancer drugs. Transition Metal Chemistry, 2007, 32, 971-980.	0.7	4
32	The power of the virtual client – using problem-based learning as a tool for integration in a pharmaceutical sciences laboratory course. Higher Education Pedagogies, 2019, 4, 462-475.	2.1	0